Eke G Gruppen1,2, Margery A Connelly3, James D Otvos3, Stephan J L Bakker2, Robin P F Dullaart1. 1. Department of Endocrinology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands. 2. Department of Nephrology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands. 3. LabCorp, Raleigh, NC, USA.
Abstract
BACKGROUND: The cholesterol-esterifying enzyme, lecithin:cholesterol acyltransferase (LCAT), is instrumental in high-density lipoprotein (HDL) remodelling. LCAT may also modify oxidative and inflammatory processes, as supported by an inverse relationship with HDL antioxidative functionality and a positive relationship with high-sensitivity C-reactive protein (hsCRP). GlycA is a recently developed proton nuclear magnetic resonance (NMR) spectroscopy-measured biomarker of inflammation whose signal originates from a subset of N-acetylglucosamine residues on the most abundant glycosylated acute-phase proteins. Plasma GlycA correlates positively with hsCRP and may predict cardiovascular disease even independent of hsCRP. Here, we tested the extent to which plasma GlycA is elevated in metabolic syndrome (MetS), and determined its relationship with LCAT activity. MATERIALS AND METHODS: Plasma GlycA, hsCRP, serum amyloid A (SAA), tumour necrosis factor-α (TNF-α) and LCAT activity were measured in 58 subjects with MetS (including 46 subjects with type 2 diabetes mellitus (T2DM)) and in 45 nondiabetic subjects without MetS. RESULTS: Plasma GlycA was higher in MetS coinciding with higher hsCRP and LCAT activity (P < 0.01 for each). In all subjects combined, GlycA was correlated positively with hsCRP, SAA and LCAT activity (P < 0.001 for each), but not with TNF-α. Age- and sex-adjusted multivariable linear regression analysis revealed that GlycA was positively associated with LCAT activity (P = 0.029), independent of the presence of MetS, T2DM, hsCRP and SAA. GlycA was unrelated to diabetes status. CONCLUSION: A pro-inflammatory glycoprotein biomarker, GlycA, is higher in MetS. Higher plasma levels of this glycoprotein biomarker relate to increased LCAT activity in the setting of MetS.
BACKGROUND: The cholesterol-esterifying enzyme, lecithin:cholesterol acyltransferase (LCAT), is instrumental in high-density lipoprotein (HDL) remodelling. LCAT may also modify oxidative and inflammatory processes, as supported by an inverse relationship with HDL antioxidative functionality and a positive relationship with high-sensitivity C-reactive protein (hsCRP). GlycA is a recently developed proton nuclear magnetic resonance (NMR) spectroscopy-measured biomarker of inflammation whose signal originates from a subset of N-acetylglucosamine residues on the most abundant glycosylated acute-phase proteins. Plasma GlycA correlates positively with hsCRP and may predict cardiovascular disease even independent of hsCRP. Here, we tested the extent to which plasma GlycA is elevated in metabolic syndrome (MetS), and determined its relationship with LCAT activity. MATERIALS AND METHODS: Plasma GlycA, hsCRP, serum amyloid A (SAA), tumour necrosis factor-α (TNF-α) and LCAT activity were measured in 58 subjects with MetS (including 46 subjects with type 2 diabetes mellitus (T2DM)) and in 45 nondiabetic subjects without MetS. RESULTS: Plasma GlycA was higher in MetS coinciding with higher hsCRP and LCAT activity (P < 0.01 for each). In all subjects combined, GlycA was correlated positively with hsCRP, SAA and LCAT activity (P < 0.001 for each), but not with TNF-α. Age- and sex-adjusted multivariable linear regression analysis revealed that GlycA was positively associated with LCAT activity (P = 0.029), independent of the presence of MetS, T2DM, hsCRP and SAA. GlycA was unrelated to diabetes status. CONCLUSION: A pro-inflammatory glycoprotein biomarker, GlycA, is higher in MetS. Higher plasma levels of this glycoprotein biomarker relate to increased LCAT activity in the setting of MetS.
Authors: Jacob L Barber; William E Kraus; Timothy S Church; James M Hagberg; Paul D Thompson; David B Bartlett; Michael W Beets; Conrad P Earnest; Kim M Huffman; Rian Q Landers-Ramos; Arthur S Leon; D C Rao; Richard L Seip; James S Skinner; Cris A Slentz; Kenneth R Wilund; Claude Bouchard; Mark A Sarzynski Journal: Atherosclerosis Date: 2018-07-26 Impact factor: 5.162
Authors: Eva Kaebisch; Taylor L Fuss; Lindsey A Vandergrift; Karin Toews; Piet Habbel; Leo L Cheng Journal: NMR Biomed Date: 2017-03-16 Impact factor: 4.044
Authors: Toby Mansell; Richard Saffery; Satvika Burugupalli; Anne-Louise Ponsonby; Mimi L K Tang; Martin O'Hely; Siroon Bekkering; Adam Alexander T Smith; Rebecca Rowland; Sarath Ranganathan; Peter D Sly; Peter Vuillermin; Fiona Collier; Peter Meikle; David Burgner Journal: Elife Date: 2022-05-10 Impact factor: 8.713
Authors: Paulette D Chandler; Akintunde O Akinkuolie; Deirdre K Tobias; Patrick R Lawler; Chungying Li; M Vinayaga Moorthy; Lu Wang; Daniel A Duprez; David R Jacobs; Robert J Glynn; James Otvos; Margery A Connelly; Wendy S Post; Paul M Ridker; JoAnn E Manson; Julie E Buring; I-Min Lee; Samia Mora Journal: PLoS One Date: 2016-11-30 Impact factor: 3.240
Authors: Scott C Ritchie; Johannes Kettunen; Marta Brozynska; Artika P Nath; Aki S Havulinna; Satu Männistö; Markus Perola; Veikko Salomaa; Mika Ala-Korpela; Gad Abraham; Peter Würtz; Michael Inouye Journal: PLoS One Date: 2019-10-23 Impact factor: 3.240
Authors: David B Emmert; Vladimir Vukovic; Nikola Dordevic; Christian X Weichenberger; Chiara Losi; Yuri D'Elia; Claudia Volpato; Vinicius V Hernandes; Martin Gögele; Luisa Foco; Giulia Pontali; Deborah Mascalzoni; Francisco S Domingues; Rupert Paulmichl; Peter P Pramstaller; Cristian Pattaro; Alessandra Rossini; Johannes Rainer; Christian Fuchsberger; Marzia De Bortoli Journal: Biomolecules Date: 2021-11-09
Authors: Margery A Connelly; James D Otvos; Irina Shalaurova; Martin P Playford; Nehal N Mehta Journal: J Transl Med Date: 2017-10-27 Impact factor: 5.531